The Global Health Body Raises Warning Over Severe Lack of Weight-Loss Medications
Less than a tenth of individuals who could benefit from GLP-1 drugs such as Wegovy have access to them, states the global health agency as it publishes its first advice on the drugs.
Considering over a billion individuals worldwide currently living with obesity, it is urging increased and just access to this class of drugs.
Per estimates, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"The new guidelines recognises that obesity is a long-term condition that can be managed with comprehensive and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major obstacles to broad availability to the injections that can help people shift substantial body mass, says the body.
GLP-1 Therapy Scarcity
Even under the present best projected scenario, the production of such drugs would only suffice for about 100 million people – less than 10% of those who need them, per the WHO.
The advice encourages nations and manufacturers to widen availability, via approaches such as patent sharing.
Exclusive production rights on the active ingredient – the core ingredient of the drug Wegovy – is set to lapse in several nations in 2026.
How Weight-Loss Injections Operate
These medications imitate a biological compound to delay gastric emptying, suppress the appetite and increase satiety so individuals eat less.
People commonly see weight reduction within a few weeks of commencing the regular doses.
Evidence points to users may regain a significant portion a year later of discontinuing the drug, because their typical food cravings return.
Being above a healthy weight raises your likelihood for experiencing diseases, like diabetes, heart disease, brain attack, and specific cancers.
Obesity concerns individuals in all nations and was associated with over three and a half million deaths worldwide in 2024, per the WHO.
